- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02041884
CBT Through Internet and Smartphones for Adults With ADHD - a Randomized Controlled Trial (Ad5)
Psychological Treatment Through Internet and Smartphones for Adults With Attention Deficit Hyperactive Disorder (ADHD) - a Randomized Controlled Trial
The purpose of this study is to further evaluate the treatment for adults with ADHD used in our previous study (clinicaltrials.gov ID NCT01659164). It will now be converted to therapist supported, internet-delivered cognitive behavioral therapy (iCBT) with an additional smartphone application and evaluated through a randomized controlled trial during 12 weeks. The patients will be randomized to one of three conditions
- an active treatment group where the intervention is based on cognitive - and dialectical behavioral therapy (CBT and DBT) and the mobile app.
- an active ICBT-treatment based on psychoeducation, a CBT stress-reduction program and Applied Relaxation, and
- treatment as usual (TAU) / waiting list.
The main objective of the study is to evaluate if both of the treatment conditions will show better outcomes than TAU regarding decreased ADHD symptoms and increased functioning and life quality.
Another objective is to evaluate if the group receiving the active iCBT treatment (based on CBT and DBT) will show better outcomes in comparison to the control group regarding ADHD symptoms, overall functioning and life quality.
Study Overview
Status
Conditions
Detailed Description
Approximately one-third of children with ADHD continue to be fully symptomatic into adulthood and many of the remainders often retain some residual problems that require treatment. Thus ADHD is a prevalent and chronic disabling disorder. Drugs provide first line treatment for adults with ADHD but are not enough for everybody, while we still lack proper evidence for promising psychological treatment. In addition to core symptoms of ADHD including regulatory difficulties of attention, activity level and impulses, difficulties with emotional regulation are common.
Follow-up studies of adults with ADHD have shown that only a few patients were offered sufficient treatment and support after the neuropsychiatric assessment and testing. The majority of adults diagnosed with ADHD are offered pharmacological treatment (stimulant medication) as the sole treatment. However, stimulant medication is not effective for up to 20-50 percent of adults as they may not experience symptom reduction or they are unable to tolerate the medication.
Consequently, the possible benefits of identifying and treating individuals with ADHD are extensive. Treatment of ADHD is preferably multimodal, i.e. consisting of more than one intervention.
Although literature regarding psychological treatment is relatively limited, studies of cognitive behavioral therapy (CBT) and dialectical behavior therapy (DBT) show that structured short-term therapies are promising in reducing ADHD related symptoms and increasing life quality. The main treatment focus is to enhance executive and organizational skills, improvement of consequence thinking and impulse control as well as emotion regulation skills. However, the range of trained psychologist in this field is rather limited. Using internet for delivering evidence-based psychological treatment can therefore be a innovative treatment alternative in order to make inaccessible treatment available to a large group of patients with ADHD.
The actual treatment project aims to evaluate if adults with ADHD can benefit from psychological treatment delivered through Internet. About 150-200 patients will be recruited through several outpatient clinics in Stockholm. They will be randomized to one of three conditions - active psychological treatment (based on CBT and DBT), an active alternative treatment where they undergo a psychoeducational support program (based on CBT) or to treatment as usual (TAU) / waiting list. The patients in the treatment conditions will have a personal contact via the internet with a psychologist within the 12 week treatment period. Assessments will be done before, during and after treatment, and after 3 and 12 months. The patients in the TAU condition will be offered iCBT treatment after they have filled out the post assessments (after 12 weeks and at 3rd month after treatment).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Internetpsykiatrienheten, Psykiatri Sydväst, SLSO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Swedish citizen
- Clinical diagnosis of AD/HD according to DSM-IV or DSM-5
- Age 18-65
- 17 or more on the Adult ADHD Self Report Scale (ASRS v1.1)
- Not medically treated for adhd symptoms, or medically treated with central stimulants or comparable substance since at least one month with no significant changes in dosage and where no change in medical treatment is anticipated during the study time frame for the participant. No change in any other medical treatment is anticipated during the study time frame for the participant.
- Participant are by investigators considered able to follow through the training protocol and take part in measures taken during the study time frame
- The participant hasn´t used drugs the last 3 months
- Access to, and ability to use the Internet and mobile phone during the study time
- ability to understand Swedish in speech and writing
Exclusion Criteria:
- Diagnosed substance abuse according to DSM-IV or DSM-5 criteria within 3 months prior to screening. Earlier episodic substance abuse is not excluding
- Co-existing psychiatric condition that investigators believe will unable the participant to follow through the training protocol and take part in measures taken during the study time frame.
- IQ ≤85 according to a neuropsychological assessment
- Suicidality risk which is assessed during the first assessment interview.
- Organic brain syndrome
- Serious somatic condition which will unable the participant to participate (through the training protocol)or, is anticipated to have a negative impact on the treatment results
- Autism spectrum disorder where the function level is deemed too low for the treatment to be carried out which is defined as moderate or severe problems scale (level 2 and 3) according to DSM-5
- Severe depression defined by >34 p on MADRS-S or by a clinician´s assessment
- Other current psychological treatment for AD/HD or previous participation in such a treatment that is deemed to interfere with the study design
- severe writing and reading disabilities
- dyslexia of such degree that it impedes participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iCBT
A skill training internet-based treatment program based on CBT and DBT interventions .
|
A skill training internet-based treatment program based on CBT and DBT interventions .
|
Active Comparator: Internet stress-reduction
Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
|
Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
|
Other: Treatment as usual (TAU)/waiting list
Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
|
Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change (from baseline) in ASRS- v 1.1
Time Frame: Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
ADHD Self Report Scale (ASRS) (self rating)
|
Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change (from baseline) in ADHD Rating Scale
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
ADHD Rating Scale - assessed by an expert rater blind to Group allocation
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in EQ-5D
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Euroqol - (self report) to measure general health and quality of life
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in ISI
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Insomnia Severity Index - (self report) to measure insomnia symptoms
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in PSS-4
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Perceived Stress Scale - (self report) to measure level of stress in everyday life
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in SDS
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Sheehan Disability Scale - (self report) to measure level of disability in everyday life
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in MADRS-S
Time Frame: Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Montgomery-Åsberg Depression Rating Scale - (self report) to measure level of depression
|
Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in DERS
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Difficulties of Emotion Regulation Scale - (self report)
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in AaQoL
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Adult ADHD Quality of Life Measure - self report
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in SWLS
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Satisfaction With Life Scale (self report) - measuring life quality.
To evaluate the impact of the intervention on quality of Life, only the first three items in the scale will be used since the last two includes the whole Life-span and not just how Life quality is percived at the moment.
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Change (from baseline) in WAI-1
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Work Ability Index (self report - one item) - a self estimation of working ability
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Changes (from baseline) in CGI-S
Time Frame: Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Clinical Global Impression - Severity scale - assessed by a blind expert rater - measuring symptom severity
|
Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment evaluation
Time Frame: during treatment and after 12 weeks of treatment (post)
|
The investigators design own questions in order to evaluate how the participants have experienced the intervention regarding to knowledge, usage of the treatment methods and possible difficulties that they have experienced during treatment.
|
during treatment and after 12 weeks of treatment (post)
|
CGI-I
Time Frame: 12 weeks (post) and after 3 and 12 months (post)
|
Clinical Global Impression - Improvement scale (rated by a clinician in order to detect level of improvement or worsening due to treatment)
|
12 weeks (post) and after 3 and 12 months (post)
|
TCS
Time Frame: Filled out by the patient at the 1st and 5th week of treatment
|
Treatment Credibility Scale (self report)
|
Filled out by the patient at the 1st and 5th week of treatment
|
*CSQ-8
Time Frame: 12 weeks (post)
|
Client Satisfaction Questionnaire-8 (self report) - in order to evaluate the treatment satisfaction
|
12 weeks (post)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Viktor Kaldo, PhD/Ass prof, Karolinska Institutet
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2014/333-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
Okinawa Institute of Science and Technology Graduate...Japan society for the promotion of science; Miyazaki International CollegeRecruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustNot yet recruiting
-
Universidad de GranadaNot yet recruiting
-
Izmir Katip Celebi UniversityDokuz Eylul UniversityNot yet recruiting
-
Seattle Children's HospitalNational Institute of Mental Health (NIMH); University of WashingtonRecruiting
-
University of California, DavisRecruiting
-
Chen LiRecruiting
-
Region SyddanmarkRecruiting
-
Hugo W. Moser Research Institute at Kennedy Krieger...Active, not recruiting
Clinical Trials on iCBT for Adults with ADHD
-
Karolinska InstitutetRegion StockholmCompleted
-
Linkoeping UniversityCompleted
-
Children's Hospital Medical Center, CincinnatiNational Institute of Mental Health (NIMH)CompletedAttention Deficit Hyperactivity Disorder | Adherence, MedicationUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Columbia UniversityCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Tufts Medical CenterCompletedAttention Deficit Hyperactivity DisorderUnited States
-
University of ReginaCompletedDepression | Anxiety | Spinal Cord InjuriesCanada
-
Karakter Kinder- en JeugdpsychiatrieRadboud University Medical Center; University of Amsterdam; European Commission; Fonds Psychische Gezondheid and other collaboratorsCompletedAttention Deficit Hyperactivity DisorderNetherlands
-
University of AarhusDanish Breast Cancer Cooperative GroupUnknown
-
Clemson UniversityRecruiting